PYC Therapeutics (ASX:PYC) selected PYC-002 as the fourth drug candidate for its clinical trial program for Phelan-McDermid syndrome, a rare genetic disease characterized by a deficiency in a protein essential for neuron communication, according to a Monday filing with the Australian bourse.
The company's pre-clinical studies showed that PYC-002 reaches the key areas of the brain affected by the disease in animal models and restores deficient protein expression to normal levels, the filing said.
The company plans to advance PYC-002 into human trials, with first-in-human studies expected to start in the first half of 2026, the filing added.
Shares of the company tumbled almost 6% in recent Monday trade.
Price (AUD): $1.42, Change: $-0.09, Percent Change: -5.67%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。